Abbisko Cayman Limited (HK:2256) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, revealed promising dose selection results for pimicotinib, a CSF-1R inhibitor aimed at treating Tenosynovial Giant Cell Tumour, at the ACoP 2024 conference. The study recommends a 50 mg daily dose for global treatment development, based on integrated pharmacokinetics, safety, and efficacy data. Investors are advised to exercise caution as the drug’s market success is not guaranteed.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.